GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (LTS:0RKL) » Definitions » 14-Day RSI

Xvivo Perfusion AB (LTS:0RKL) 14-Day RSI : 51.92 (As of Dec. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xvivo Perfusion AB 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-15), Xvivo Perfusion AB's 14-Day RSI is 51.92.

The industry rank for Xvivo Perfusion AB's 14-Day RSI or its related term are showing as below:

LTS:0RKL's 14-Day RSI is ranked worse than
68.59% of 885 companies
in the Medical Devices & Instruments industry
Industry Median: 48 vs LTS:0RKL: 51.92

Competitive Comparison of Xvivo Perfusion AB's 14-Day RSI

For the Medical Devices subindustry, Xvivo Perfusion AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's 14-Day RSI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's 14-Day RSI falls into.



Xvivo Perfusion AB  (LTS:0RKL) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (LTS:0RKL) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Xvivo Perfusion AB 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB Business Description

Traded in Other Exchanges
Address
Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines